TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 14703887
Drug: Heater probe
Normalized name: norethindrone
DrugBank: Norethisterone (DB00717)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Heater probe thermocoagulation plus hypertonic saline‐epinephrine injection
Study: 9873176
Drug: Itraconazole (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itraconazole (200 mg twice daily)
Study: 1313682
Drug: Amphotericin B
Normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amphotericin B (0.3 mg/kg daily) plus flucytosine (150 mg/kg daily)
Study: 31204320
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (No preparation)
Study: 26967937
Drug: Subthalamic nucleus
Normalized name: Sus scrofa thalamus lateral geniculate nucleus preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subthalamic nucleus deep brain stimulation (STN‐DBS) + optimal drug therapy (ODT)
Study: 26306000
Drug: Optimal drug
Normalized name: Optima Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal drug therapy (ODT)
Study: 25267694
Drug: Heart rate
Normalized name: porcine heart preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heart rate at 80 bpm and tidal volume at 6 mL/kg
Study: 25267694
Drug: Heart rate
Normalized name: porcine heart preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heart rate at 110 bpm and tidal volume at 6 mL/kg
Study: 25267694
Drug: Heart rate
Normalized name: porcine heart preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heart rate at 80 bpm and tidal volume at 10 mL/kg
Study: 25267694
Drug: Heart rate
Normalized name: porcine heart preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heart rate at 110 bpm and tidal volume at 10 mL/kg
Study: 25267694
Drug: Increasing tidal
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increasing tidal volume from 6 mL/kg to 10 mL/kg
Study: 27181367
Drug: Oral Appliance
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral Appliance (OA) therapy
Study: 15754377
Drug: Budesonide 6
Normalized name: budesonide 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide 6 mg/d and UDCA 15 mg/kg/d
Study: 15754377
Drug: UDCA 15
Normalized name: UDCA
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: UDCA 15 mg/kg/d
Study: 10549401
Drug: Allopurinol (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allopurinol (300 mg daily for 4 weeks)
Study: 2505187
Drug: L-carnitine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine (2 g/day) for 6 weeks
Study: 2457403
Drug: Bumetanide 1
Normalized name: bumetanide 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bumetanide 1 mg
Study: 1277709
Drug: Bumetanide 1
Normalized name: bumetanide 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bumetanide 1 mg and Furosemide 40 mg
Study: 30699846
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) 3 g/day
Study: 21199271
Drug: Low-dosage sulphonylurea
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dosage sulphonylurea (1-mg glimepiride; Amaryl)
Study: 7890255
Drug: Outpatient treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Outpatient treatment group with incomplete response
Study: 23806096
Drug: Simultaneous infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simultaneous infusion of GLP-1 and Vitamin C
Study: 21360201
Drug: Ice slurry
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ice slurry ingestion (1.25 g kg(‐1), -1°C)
Study: 19961044
Drug: Single injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single injection lumbar plexus and sciatic nerve blocks
Study: 18046188
Drug: Carbohydrate (CHO)
Normalized name: pyrrolidone carboxylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate (CHO) supplementation (20% maltodextrin at 0.6 g.kg FFM.h)
Study: 15535402
Drug: HIV drug
Normalized name: HIV
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIV drug resistance testing
Study: 31808598
Drug: Oral bambuterol
Normalized name: bambuterol
DrugBank: Bambuterol (DB01408)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral bambuterol hydrochloride (10 mg, once daily, for 3 days)
Study: 31411184
Drug: Double antithrombotic
Normalized name: antithrombin III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double antithrombotic therapy (DT)
Study: 31411184
Drug: Triple antithrombotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple antithrombotic therapy (TT)
Study: 25994179
Drug: Etanercept 50
Normalized name: etanercept 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept 50 mg biweekly (BIW)
Study: 24861696
Drug: Etanercept 50
Normalized name: etanercept 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept 50 mg QW/QW
Study: 24861696
Drug: Etanercept 50
Normalized name: etanercept 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept 50 mg BIW/QW
Study: 22129348
Drug: Dietary protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary protein at 350 g/kg and lipid at 80 g/kg
Study: 22129348
Drug: Dietary protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary protein at 300 g/kg and lipid at 60 g/kg
Study: 22129348
Drug: Dietary lipid
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary lipid at 80 g/kg
Study: 19694385
Drug: Qianlie Beixi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qianlie Beixi Capsule
Study: 19694385
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (compound tablets of zinc and protein)
Study: 12720590
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg Zn/d for 14 weeks followed by 3 mg Cu/d for 8 weeks
Study: 10972662
Drug: Intravenous calcitriol
Normalized name: Calcitriol
DrugBank: Calcitriol (DB00136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous calcitriol (1.5 mg/m2 body surface area)
Study: 10972662
Drug: Oral calcitriol
Normalized name: Calcitriol
DrugBank: Calcitriol (DB00136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral calcitriol (1.5 mg/m2 body surface area)
Study: 10972662
Drug: Control values
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control values for Sr absorption (separate group of children with CRF)
Study: 10972662
Drug: Intravenous calcitriol
Normalized name: Calcitriol
DrugBank: Calcitriol (DB00136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous calcitriol and Oral calcitriol
Study: 8439828
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg nitrendipine initial dose
Study: 8439828
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg nitrendipine twice daily
Study: 8439828
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg nitrendipine once daily
Study: 8439828
Drug: Chronic nitrendipine
Normalized name: nitrendipine
DrugBank: Nitrendipine (DB01054)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chronic nitrendipine therapy
Study: 3301560
Drug: Flunarizine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunarizine (10 mg/die for patients <70 kg; 15 mg/die for patients >70 kg)
Study: 30200895
Drug: Standard prednisolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard prednisolone plus high-dose mizoribine (10 mg/kg/day once daily for 2 years)
Study: 11156638
Drug: Budesonide 6
Normalized name: budesonide 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide 6 mg once daily
Study: 10341672
Drug: Low-fat meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-fat meal (0.2 g/kg body weight; mean 14 g)
Study: 10341672
Drug: High-fat meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-fat meal (0.6 g/kg body weight; mean 43 g)
Study: 19670088
Drug: Radiation dose
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radiation dose of 24 Gy
Study: 19670088
Drug: Radiation dose
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radiation dose of 27 Gy
Study: 23014489
Drug: Whole-grain (WG)
Normalized name: rice (whole grain) allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole-grain (WG) foods (80 g/d)
Study: 23014489
Drug: Refined-grain (RG)
Normalized name: barley grain
DrugBank: Barley (DB10506)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Refined-grain (RG) foods (0 g/d)
Study: 19954479
Drug: Rheopheresis treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rheopheresis treatment (RT) twice a week for a total of ten treatments, along with high-dose supplementation of zinc and vitamins A, E, and beta-carotene.
Study: 19954479
Drug: Rheopheresis treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rheopheresis treatment (RT) after the fifth treatment.
Study: 19954479
Drug: Rheopheresis treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rheopheresis treatment (RT) compared to before RT at time 1 and time 2.
Study: 17678776
Drug: Epidural analgesia
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural analgesia with propofol target-controlled infusion
Study: 17678776
Drug: Alfentanil with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfentanil with propofol target-controlled infusion
Study: 17678776
Drug: High-dose remifentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose remifentanil with propofol target-controlled infusion
Study: 17678776
Drug: Low-dose remifentanil
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose remifentanil with propofol target-controlled infusion
Study: 15181127
Drug: Dopamine agonist
Normalized name: Dopamine agonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine agonist dosage in PD patients
Study: 3481318
Drug: Ciprofloxacin 250
Normalized name: ciprofloxacin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 250 mg (twice daily)
Study: 3481318
Drug: Enoxacin 400
Normalized name: enoxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxacin 400 mg (twice daily)
Study: 3481318
Drug: Ofloxacin 200
Normalized name: ofloxacin 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ofloxacin 200 mg (twice daily)
Study: 22342916
Drug: HBsAg-1018 ISS
Normalized name: HBSAG
DrugBank: Hepatitis B Vaccine (Recombinant) (DB11627)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HBsAg-1018 ISS vaccine
Study: 22342916
Drug: Engerix-B(®) (licensed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Engerix-B(®) (licensed hepatitis B vaccine)
Study: 21047593
Drug: Serum PSA
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum PSA screening with a cut-off of 4 ng/ml
Study: 21047593
Drug: Serum PSA
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum PSA screening with a cut-off of 3 ng/ml
Study: 17548243
Drug: Sertraline 50
Normalized name: sertraline 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline 50 mg once per day
Study: 16262574
Drug: Laser treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser treatment with exercise protocol for 10 sessions over 2 weeks.
Study: 16262574
Drug: Placebo laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo laser treatment with exercise protocol for 10 sessions over 2 weeks.
Study: 11905448
Drug: Dental auscultation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dental auscultation and traditional oral health care education
Study: 11905448
Drug: Traditional oral
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional oral health care education
Study: 10069683
Drug: Xamoterol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xamoterol (100 mg, p.o.)
Study: 10069683
Drug: Xamoterol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xamoterol (200 mg, p.o.)
Study: 10069683
Drug: Celiprolol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celiprolol (200 mg, p.o.)
Study: 10069683
Drug: Celiprolol (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celiprolol (600 mg, p.o.)
Study: 10069683
Drug: Celiprolol (1,200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celiprolol (1,200 mg, p.o.)
Study: 10069683
Drug: Celiprolol (after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celiprolol (after terbutaline treatment)
Study: 7567313
Drug: Ceftibuten suspension
Normalized name: Ceftibuten
DrugBank: Ceftibuten (DB01415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ceftibuten suspension (9 mg/kg once daily, max 400 mg)
Study: 1967592
Drug: Intravenous fenoldopam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous fenoldopam mesylate, infused at a maximal dose increment of 0.2 microgram/kg/min, with a maximal infusion rate of 1.5 micrograms/kg/min.
Study: 1967592
Drug: Sodium nitroprusside,
Normalized name: Sodium Nitroprusside, 25 mg/mL intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium nitroprusside, infused at a maximal dose increment of 1 microgram/kg/min, with a maximal infusion rate of 8 micrograms/kg/min.
Study: 7387812
Drug: Diazoxide (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazoxide (300 mg i.v.) during untreated condition (n=29)
Study: 7387812
Drug: Diazoxide (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazoxide (300 mg i.v.) during treatment with propranolol (320 mg/day) (n=15)
Study: 7387812
Drug: Diazoxide (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazoxide (300 mg i.v.) during treatment with propranolol plus atropine (0.04 mg/kg) (n=12)
Study: 7387812
Drug: Diazoxide (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazoxide (300 mg i.v.) during propranolol (n=15)
Study: 7387812
Drug: Diazoxide (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazoxide (300 mg i.v.) without propranolol (n=15)
Study: 7387812
Drug: Diazoxide (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazoxide (300 mg i.v.) during propranolol plus atropine (n=12)
Study: 25517261
Drug: Fentanyl transdermal
Normalized name: Fentanyl Transdermal System
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl transdermal patch (Durogesic® D-TRANS)
Study: 7848930
Drug: Epidural morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural morphine sulfate (MSO4) via continuous infusion (initial bolus of 0.03 mg/kg, infusion of 0.01% morphine at 5 mL/hour, titrated from 0.2 to 1.0 mg/hour)
Study: 7848930
Drug: Epidural morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural morphine sulfate (MSO4) via intermittent bolus (initial bolus of 0.07 mg/kg, followed by 2-5 mg on demand)
Study: 3907037
Drug: High fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High fluid replacement (total volume of urine output + 30 ml/hr)
Study: 3907037
Drug: Low fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low fluid replacement (constant 125 ml/hr)
Study: 24684771
Drug: PRT‐201 at
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRT‐201 at 10 μg
Study: 24684771
Drug: PRT‐201 at
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRT‐201 at 30 μg
Study: 24684771
Drug: PRT‐201 at
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRT‐201 at 10 μg (RCF subset)
Study: 24684771
Drug: PRT‐201 at
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRT‐201 at 30 μg (RCF subset)
Study: 22525444
Drug: Supplemental oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplemental oxygen (nasal prongs, 1-2 L/min flow)
Study: 17663099
Drug: Drug-separated moxibustion
Normalized name: serrated swimming crab, cooked preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-separated moxibustion at the navel
Study: 17663099
Drug: Western medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medicine (vitamin E capsules, 0.1 g twice daily)
Study: 14997748
Drug: Aromatase inhibitors
Normalized name: Aromatase inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aromatase inhibitors (Als)
Study: 14997748
Drug: Neo-adjuvant endocrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neo-adjuvant endocrine therapy
Study: 14997748
Drug: Surrogate markers
Normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surrogate markers in neo-adjuvant endocrine treatment
Study: 11126208
Drug: Caffeine/Ephedrine (CE)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine/Ephedrine (CE) mixture (100 mg/10 mg for those <80 kg, 200 mg/20 mg for those >80 kg, taken three times daily)
Study: 1571917
Drug: Single-dose TBI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose TBI (1000 cGy midplane, 800 cGy lungs) at HIGH dose rate (15 cGy/min)
Study: 1571917
Drug: Single-dose TBI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose TBI (1000 cGy midplane, 800 cGy lungs) at LOW dose rate (6 cGy/min)
Study: 1571917
Drug: Fractionated-dose TBI
Normalized name: Poliovirus, inactivated, fractional-dose (fIPV)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fractionated-dose TBI (1200 cGy midplane, 900 cGy lungs) at HIGH dose rate (6 cGy/min)
Study: 1571917
Drug: Fractionated-dose TBI
Normalized name: Poliovirus, inactivated, fractional-dose (fIPV)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fractionated-dose TBI (1200 cGy midplane, 900 cGy lungs) at LOW dose rate (3 cGy/min)
Study: 1571917
Drug: Single-dose HIGH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose HIGH instantaneous dose rate TBI
Study: 30647034
Drug: Cardiac output-guided
Normalized name: Leonurus cardiaca extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardiac output-guided fluid therapy with low-dose inotrope infusion
Study: 24217699
Drug: Nitroxoline (NTX)
Normalized name: nitroxoline
DrugBank: Nitroxoline (DB01422)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroxoline (NTX) at 250 mg
Study: 24217699
Drug: Trimethoprim (TMP)
Normalized name: Trimethoprim
DrugBank: Trimethoprim (DB00440)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Trimethoprim (TMP) at 200 mg
Study: 24217699
Drug: Nitroxoline (NTX)
Normalized name: nitroxoline
DrugBank: Nitroxoline (DB01422)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroxoline (NTX) at 250 mg three times a day
Study: 11306208
Drug: Transdermal gel
Normalized name: Androgel 1% Transdermal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal gel (1.0 mg estradiol daily)
Study: 10465378
Drug: Transdermal patch
Normalized name: TRANSDERMAL PATCH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal patch (50 microg/24 h)
Study: 9336557
Drug: 200 mg/day
Normalized name: alpelisib 200 mg/day (200 mg x 1) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg/day of Panax ginseng C.A. Meyer (G115)
Study: 9336557
Drug: 400 mg/day
Normalized name: ribociclib succinate 400 mg/day (200 mg x 2) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg/day of Panax ginseng C.A. Meyer (G115)
Study: 26487588
Drug: Chemotherapy initiation
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Chemotherapy initiation within 25 days post-surgery
Study: 26487588
Drug: Chemotherapy initiation
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Chemotherapy initiation after 25 days post-surgery
Study: 24598777
Drug: Internet-based treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based treatment with email support by a urotherapist
Study: 24598777
Drug: Postal treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postal treatment program
Study: 2173011
Drug: Joint alpha-
Normalized name: One-Alpha
DrugBank: Alfacalcidol (DB01436)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Joint alpha- and beta-adrenoreceptor pharmacological blocker
Study: 31318648
Drug: Mesenchymal precursor
Normalized name: Allogeneic mesenchymal precursor cell
DrugBank: Rexlemestrocel-L (DB17606)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mesenchymal precursor cells as immunotherapy
Study: 27808522
Drug: Reaching agreements
Normalized name: cetylpyridinium chloride Mouthwash [Breath-Away]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reaching agreements on specific issues (e.g., custody, child support)
Study: 25781193
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 supplementation (2000 IUs daily for 3 months)
Study: 19481320
Drug: Intradermal (ID)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal (ID) vaccination (10 microg of vaccine every week for 8 weeks)
Study: 19481320
Drug: Intramuscular (IM)
Normalized name: intramuscular immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular (IM) vaccination (40 microg of vaccine at weeks 1 and 8)
Study: 15109507
Drug: Topical clonazepam
Normalized name: Clonazepam
DrugBank: Clonazepam (DB01068)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical clonazepam (1 mg tablet, sucked three times a day for 14 days)
Study: 11295622
Drug: Daily dietary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily dietary supplementation with selenium; dosage and duration not specified.
Study: 9085968
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (TA) 15 mg/kg IV followed by two additional doses of 10 mg/kg each
Study: 8204940
Drug: IL2 as
Normalized name: DAB(SUB 389)IL2
Approvals — FDA: no, EMA: no, PMDA: no
Description: IL2 as a continuous infusion or high doses intravenous IL2 combined with alpha interferon (IFN) or a combination of IL2 and IFN as subcutaneous low doses
Study: 8204940
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of IL2 with Tumor Necrosis Factor (TNF) as rescue treatment
Study: 25689245
Drug: Glargine insulin
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Glargine insulin
Study: 27091835
Drug: RI-in-PN (Regular
Approvals — FDA: no, EMA: no, PMDA: no
Description: RI-in-PN (Regular Insulin in Parenteral Nutrition)
Study: 23642372
Drug: Focal laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Focal laser photocoagulation plus intravitreal ranibizumab (L+R)
Study: 23642372
Drug: Focal laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Focal laser photocoagulation plus intravitreal bevacizumab (L+B)